Lee Anita Y H, Chappell Derek L, Bak Monika J, Judo Michael, Liang Linda, Churakova Tatyana, Ayanoglu Gulesi, Castro-Perez Jose, Zhou Haihong, Previs Stephen, Souza Sandra C, Lassman Michael E, Laterza Omar F
Translational Biomarkers, Merck Research Laboratories, Rahway, NJ;
NNF Center for Basic Metabolic Research, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
Clin Chem. 2016 Jan;62(1):227-35. doi: 10.1373/clinchem.2015.244251. Epub 2015 Oct 1.
Proglucagon-derived peptides (PGDPs), which include glucagon-like peptide (GLP)-1, glucagon, and oxyntomodulin, are key regulators of glucose homeostasis and satiety. These peptide hormones are typically measured with immuno-based assays (e.g., ELISA, RIA), which often suffer from issues of selectivity.
We developed a multiplexed assay for measuring PGDPs including GLP-1 (7-36) amide, GLP-1 (9-36) amide, glucagon, and oxyntomodulin by mass spectrometry and used this assay to examine the effect of a meal tolerance test on circulating concentrations of these hormones. Participants fasted overnight and were either given a meal (n = 8) or continued to fast (n = 4), with multiple blood collections over the course of 3 h. Plasma samples were analyzed by microflow immunoaffinity (IA)-LC-MS/MS with an isotope dilution strategy.
Assay performance characteristics were examined and established during analytical validation for all peptides. Intra- and interassay imprecision were found to be 2.2%-10.7% and 6.8%-22.5%, respectively. Spike recovery was >76%, and dilution linearity was established up to a 16-fold dilution. Immediately after the meal tolerance test, GLP-1 and oxyntomodulin concentrations increased and had an almost identical temporal relationship, and glucagon concentrations increased with a slight delay.
IA-LC-MS/MS was used for the simultaneous and selective measurement of PGDPs. This work includes the first indication of the physiological concentrations and modulation of oxyntomodulin after a meal.
胰高血糖素原衍生肽(PGDPs),包括胰高血糖素样肽(GLP)-1、胰高血糖素和胃抑制肽,是葡萄糖稳态和饱腹感的关键调节因子。这些肽类激素通常采用基于免疫的检测方法(如酶联免疫吸附测定法、放射免疫测定法)进行检测,而这些方法往往存在选择性问题。
我们开发了一种用于通过质谱法测量包括GLP-1(7-36)酰胺、GLP-1(9-36)酰胺、胰高血糖素和胃抑制肽在内的PGDPs的多重检测方法,并使用该检测方法来研究糖耐量试验对这些激素循环浓度的影响。参与者禁食过夜,然后一部分人进食(n = 8),另一部分人继续禁食(n = 4),在3小时内进行多次血液采集。血浆样本采用微流免疫亲和(IA)-液相色谱-串联质谱法结合同位素稀释策略进行分析。
在所有肽的分析验证过程中检查并确定了检测性能特征。批内和批间不精密度分别为2.2%-10.7%和6.8%-22.5%。加标回收率>76%,并且建立了高达16倍稀释的稀释线性关系。糖耐量试验后,GLP-1和胃抑制肽的浓度立即升高,且具有几乎相同的时间关系,胰高血糖素浓度略有延迟升高。
IA-液相色谱-串联质谱法用于同时选择性测量PGDPs。这项工作首次表明了进食后胃抑制肽的生理浓度及其调节情况。